Baker Danial E
Hosp Pharm. 2017 Apr;52(4):302-305. doi: 10.1310/hpj5204-302.
Each month, subscribers to receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of publishes selected reviews in this column. For more information about contact Wolters Kluwer customer service at 866-397-3433. The April 2017 monograph topics are deflazacort, plecanatide, delafloxacin, oxymetazoline hydrochloride 1% cream, and betrixaban. The DUE is on plecanatide.
每月，订阅者会收到5至6篇关于新发布或处于3期临床试验后期阶段药物的资料详实的专题论文。这些专题论文面向药学与治疗学委员会。订阅者还会每月收到1页关于对议程以及药学/护理在职培训有用药物的简要专题论文。每月还会提供一份全面的目标药物利用评估/用药评估（DUE/MUE）。订阅后，专题论文可供订阅者在线获取。专题论文可进行定制以满足机构的需求。通过合作，[此处原文缺失相关内容]在本专栏发表精选评论。如需更多信息，请致电866 - 397 - 3433联系威科集团客服。2017年4月专题论文的主题是地夫可特、普卡那肽、德拉氟沙星、1%盐酸羟甲唑啉乳膏和贝曲西班。DUE是关于普卡那肽的。
